NasdaqGM:ADMABiotechs
Assessing ADMA Biologics (ADMA) Valuation After Q3 Beat, FDA Yield Win, and Raised Revenue Guidance
ADMA Biologics (ADMA) just checked several key boxes for investors, with third quarter revenue topping expectations, FDA sign off on yield enhanced batches, and a higher 2025 sales outlook tied to Asceniv momentum.
See our latest analysis for ADMA Biologics.
The upbeat Q3 update and higher 2025 revenue guidance come on top of a powerful run, with a roughly 31% one month share price return and an exceptional five year total shareholder return that signals sustained, long term momentum.
If...